Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Editorial

Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

Naoshi Nishida

Clin Mol Hepatol. 2025;31(1):311-315. Published online September 3, 2024

DOI: https://doi.org/10.3350/cmh.2024.0739

View: 847 Download: 64 Crossref: 2

Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”

Naoshi Nishida

Clin Mol Hepatol. 2024;30(4):682-688. Published online May 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0324

View: 1813 Download: 102 Crossref: 1

Metabolic disease as a risk of hepatocellular carcinoma

Naoshi Nishida

Clin Mol Hepatol. 2021;27(1):87-90. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0302

View: 5827 Download: 119 Web of Science: 15 Crossref: 17

Long-term prognosis and management of hepatocellular carcinoma after curative treatment

Naoshi Nishida

Clin Mol Hepatol. 2020;26(4):480-483. Published online September 21, 2020

DOI: https://doi.org/10.3350/cmh.2020.0208

View: 6186 Download: 105 Web of Science: 12 Crossref: 11

Genetic Insights into Sarcomatoid Hepatocellular Carcinoma: Critical Role of ARID2 in Pathogenesis and Immune Feature

Naoshi Nishida

Received January 19, 2025 Accepted January 23, 2025

DOI: https://doi.org/10.3350/cmh.2025.0071 [Accepted]

View: 234 Download: 17

Original Article

Molecular Classification of Hepatocellular Carcinoma based on Zoned Metabolic Feature and Oncogenic Signaling Pathway

Tomoko Aoki, Naoshi Nishida, Yutaka Kurebayashi, Kazuko Sakai, Naoto Fujiwara, Masakatsu Tsurusaki, Kohei Hanaoka, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Hiroshi Ida, Kazuomi Ueshima, Yasunori Minami, Atsushi Takebe, Takaaki Murase, Keiko Kamei, Takuya Nakai, Ippei Matsumoto, Kazuto Nishio, Masatoshi Kudo

Received December 3, 2024 Accepted March 7, 2025

DOI: https://doi.org/10.3350/cmh.2024.1088 [Accepted]

View: 363 Download: 41

1 |

Viewed By 6911	MAFLD: How is it different from NAFLD?
Viewed By 6073	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 5258	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5120	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4646	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 295	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 266	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 170	MAFLD: How is it different from NAFLD?
Cited By 92	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 88	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search